Canadian Cancer Trials Group Bulletins

Trial Management Group


Trials Closed to Accrual

Canadian Cancer Trials Group BRC.2 (ECOG 1505) -- A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab For Patients with Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)

and

Canadian Cancer Trials Group BRC.2E -- A Prospective Economic Analysis of Canadian Cancer Trials Group BRC.2 (ECOG 1505)

were closed to accrual on September 20, 2013. All Canadian patients will have completed protocol therapy by September 30, 2014.

Thanks go out to all participating member centres, staff and patients for contributing to the success of this trial.